Evidence map›Paper›PMID 37305162›Full record

ArticleOncology research2021

Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (

Motawa E El-Houseini, Mostafa S Arafat, Ahmed M El-Husseiny, Islam M Kasem, Mahmoud M Kamel, Ahmed H El-Habashy, Medhat M Khafagy, Enas M Radwan, Maha H Helal, Mona S Abdellateif

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Motawa E El-HouseiniMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Mostafa S ArafatBiotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Ahmed M El-HusseinyZoology department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Islam M KasemBiotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
Mahmoud M KamelClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Ahmed H El-HabashyDepartment of Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Medhat M KhafagySurgical Oncology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Enas M RadwanClinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Maha H HelalRadio-Diagnosis Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Mona S AbdellateifMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs ( Conclusion:

Indexed as

NeoplasmsVascular Endothelial Growth Factor AAnimalsCoculture TechniquesDown-RegulationFemaleForkhead Transcription FactorsHumansImmunotherapyForkhead Transcription FactorsVascular Endothelial Growth Factor Abreast cancerCTLA4ImmunotherapyPD1TIDCsTILs

Identifiers

PMID37305162
PMCPMC10207991
OpenAlexW4312891878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.